Related Experiment Videos
Role of lipoproteins in progressive renal disease
1Department of Clinical Chemistry, Grosshadern Clinic, University of Munich, Germany.
Insights
Lipid abnormalities like hyperlipoproteinemia are common in kidney disease, potentially causing glomerular damage. Managing these lipid issues may improve long-term kidney health.
Area of Science:
- Nephrology
- Lipidology
- Pathology
Background:
- Renal diseases frequently present with hyperlipoproteinemia and dyslipoproteinemia.
- Nephrotic syndrome consistently shows elevated total serum cholesterol and triglycerides.
- Dyslipoproteinemia affects a significant portion of patients undergoing hemodialysis and post-renal transplantation.
Purpose of the Study:
- To explore the link between lipid abnormalities and kidney damage.
- To investigate the role of lipoproteins in progressive renal disease.
- To highlight the potential benefits of correcting dyslipoproteinemia in renal patients.
Main Methods:
- Review of clinical observations in patients with renal insufficiency and post-transplant recipients.
- Analysis of experimental animal studies on lipid-induced kidney damage.
- Inclusion of in vitro cell-culture studies on human glomerular cells.
Main Results:
- Hypertriglyceridemia and dyslipoproteinemia are prevalent in hemodialysis patients.
- Glucocorticoids and cyclosporin A can exacerbate hypercholesterolemia and hyperlipoproteinemia post-transplantation.
- Lipids are implicated in kidney damage, leading to glomerulosclerosis.
Conclusions:
- Lipoproteins are strongly indicated as critical players in mesangial cell damage and progressive renal disease.
- Therapeutic interventions targeting dyslipoproteinemia may offer long-term benefits for renal disease amelioration.
- Understanding lipid metabolism is crucial for managing and treating kidney diseases.
Abstract:
Renal diseases are often associated with hyperlipoproteinemia and dyslipoproteinemia. Total serum cholesterol and triglycerides are increased in nephrotic syndrome regardless of etiology. Approximately 40 to 50% of patients with renal insufficiency requiring hemodialysis show hypertriglyceridemia and dyslipoproteinemia. During chronic hemodialysis, high doses of unfractionated heparin deplete post-heparin lipolytic activity and aggravate dyslipoproteinemia. Hypercholestrolemia and hyperlipoproteinemia are often encountered in patients taking glucocorticoids and cyclosporin A after renal transplantation. Observations in experimental animals and in patients with genetically determined and acquired hyperlipidemias suggest that lipids can damage the kidney and lead to glomerulosclerosis. In vitro cell-culture studies of human glomerular cells have been useful in providing information on lipid-induced glomerular damage. Thus, there are strong indications that lipoproteins may play a critical role in the development of mesangial cell damage and progressive renal disease. Therapeutic measures that reduce and correct dyslipoproteinemia in renal disease may have long-term beneficial effects on the amelioration of renal disease.